These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

91 related items for PubMed ID: 17497046

  • 1. Eprosartan in secondary prevention of stroke: the economic evidence.
    Wessels F.
    Cardiovasc J Afr; 2007; 18(2):95-6. PubMed ID: 17497046
    [No Abstract] [Full Text] [Related]

  • 2. Cost-utility analysis of eprosartan compared to enalapril in primary prevention and nitrendipine in secondary prevention in Europe--the HEALTH model.
    Schwander B, Gradl B, Zöllner Y, Lindgren P, Diener HC, Lüders S, Schrader J, Villar FA, Greiner W, Jönsson B.
    Value Health; 2009 Sep; 12(6):857-71. PubMed ID: 19508663
    [Abstract] [Full Text] [Related]

  • 3. [Adjustment of antihypertensive therapy to a generic eprosartan preparation. Results of a non-interventional study].
    Nüdling S, Kahner-Gröne S, Köneke D, Marggraf K, Palissa H.
    MMW Fortschr Med; 2010 Oct 14; 152 Suppl 3():96-101. PubMed ID: 21595153
    [No Abstract] [Full Text] [Related]

  • 4. Eprosartan (Teveten) offers new opportunities to prevent a second stroke.
    Cardiovasc J S Afr; 2005 Oct 14; 16(1):56. PubMed ID: 15778775
    [No Abstract] [Full Text] [Related]

  • 5. Angiotensin receptor blockers and secondary stroke prevention: the MOSES study.
    Dowlatshahi D, Hill MD.
    Expert Rev Cardiovasc Ther; 2009 May 14; 7(5):459-64. PubMed ID: 19419253
    [Abstract] [Full Text] [Related]

  • 6. [Stroke prevention. Is there an added value to RAS inhibition?].
    MMW Fortschr Med; 2000 Feb 10; 142(6):62-3. PubMed ID: 10832360
    [No Abstract] [Full Text] [Related]

  • 7. Preventing cerebrovascular and cardiovascular events after stroke: eprosartan or nitrendipine?
    Johnston SC.
    Nat Clin Pract Neurol; 2006 Jan 10; 2(1):24-5. PubMed ID: 16932517
    [No Abstract] [Full Text] [Related]

  • 8. Does the MOSES study provide sufficient evidence for Eprosartan against Nitrendipine?
    Larsen K, Hornnes N, Boysen G.
    Stroke; 2006 Jun 10; 37(6):1357; author reply 1358. PubMed ID: 16645128
    [No Abstract] [Full Text] [Related]

  • 9. Costs of eprosartan versus diuretics for treatment of hypertension in a geriatric population: an observational, open-label, multicentre study.
    Gregori JA, Nuñez JF, Domínguez-Gil A, MEFASA Group.
    Drugs Aging; 2009 Jun 10; 26(7):617-26. PubMed ID: 19655828
    [Abstract] [Full Text] [Related]

  • 10. Risk reduction by preventing stroke: need for blockade of angiotensin II and catecholamines?
    Rupp H.
    Curr Med Res Opin; 2007 Nov 10; 23 Suppl 5():S25-9. PubMed ID: 18093411
    [Abstract] [Full Text] [Related]

  • 11. Unique dual mechanism of action of eprosartan: effects on systolic blood pressure, pulse pressure, risk of stroke and cognitive decline.
    Ram CV, Rudmann MA.
    Expert Rev Cardiovasc Ther; 2007 Nov 10; 5(6):1003-11. PubMed ID: 18035916
    [Abstract] [Full Text] [Related]

  • 12. [Effect of a combination of teveten and prestarium in patients with chronic heart failure].
    Gorgoshidze ML, Abashidze TB.
    Georgian Med News; 2005 Jun 10; (123):18-21. PubMed ID: 16052048
    [Abstract] [Full Text] [Related]

  • 13. Introduction: The pharmacological profile of eprosartan--implications for cerebrovascular and cardiovascular risk reduction.
    de la Sierra A, Ram CV.
    Curr Med Res Opin; 2007 Nov 10; 23 Suppl 5():S1-3. PubMed ID: 18093407
    [Abstract] [Full Text] [Related]

  • 14. Observational Study on Cognitive function And systolic blood pressure Reduction (OSCAR): preliminary analysis of 6-month data from > 10,000 patients and review of the literature.
    Shlyakhto E.
    Curr Med Res Opin; 2007 Nov 10; 23 Suppl 5():S13-8. PubMed ID: 18093409
    [Abstract] [Full Text] [Related]

  • 15. Teveten (eprosartan) reduces future risk in hypertensive stroke patients.
    Cardiovasc J S Afr; 2004 Nov 10; 15(5):255-6. PubMed ID: 15483740
    [No Abstract] [Full Text] [Related]

  • 16. An economic evaluation of a perindopril-based blood pressure lowering regimen for patients who have suffered a cerebrovascular event.
    Tavakoli M, Pumford N, Woodward M, Doney A, Chalmers J, MacMahon S, Macwalter R.
    Eur J Health Econ; 2009 Feb 10; 10(1):111-9. PubMed ID: 18446392
    [Abstract] [Full Text] [Related]

  • 17. Angiotensin blockade with eprosartan: vascular and functional implications.
    Ram CV.
    Curr Med Res Opin; 2007 Nov 10; 23 Suppl 5():S5-11. PubMed ID: 18093408
    [Abstract] [Full Text] [Related]

  • 18. Effectiveness of eprosartan in diabetic hypertensive patients.
    Robles NR, Martín-Agueda B, López-Muñoz F, Alamo C, Investigators of ESTEPP Study.
    Eur J Intern Med; 2008 Jan 10; 19(1):27-31. PubMed ID: 18206598
    [Abstract] [Full Text] [Related]

  • 19. Superoxide dismutase and catalase anti-oxidant activity in leucocyte lysates from hypertensive patients: effects of eprosartan treatment.
    Labiós M, Martínez M, Gabriel F, Guiral V, Dasi F, Beltrán B, Muñoz A.
    J Renin Angiotensin Aldosterone Syst; 2009 Mar 10; 10(1):24-30. PubMed ID: 19286755
    [Abstract] [Full Text] [Related]

  • 20. [Antihypertensive drug. Dual action lowers blood pressure more effectively].
    MMW Fortschr Med; 2001 May 03; 143(18):49. PubMed ID: 11387709
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.